EMEA-002303-PIP01-17-M04
Submitted by Anonymous (not verified) on 14 March 2025 - 11:52
EMEA-002303-PIP01-17-M04
User guide for micro, small and medium-sized enterprises
Submitted by Anonymous (not verified) on 14 March 2025 - 11:40
User guide for micro, small and medium-sized enterprises
EMA Management Board: highlights of March 2025 meeting
Submitted by Anonymous (not verified) on 14 March 2025 - 11:30
EMA Management Board: highlights of March 2025 meeting
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 10-13 March 2025
Submitted by Anonymous (not verified) on 14 March 2025 - 11:00
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 10-13 March 2025
EMEA-002141-PIP01-17-M04
Submitted by Anonymous (not verified) on 14 March 2025 - 10:54
EMEA-002141-PIP01-17-M04
EMEA-001949-PIP02-18-M04
Submitted by Anonymous (not verified) on 14 March 2025 - 10:32
EMEA-001949-PIP02-18-M04
EMEA-001949-PIP01-16-M06
Submitted by Anonymous (not verified) on 14 March 2025 - 9:57
EMEA-001949-PIP01-16-M06
Opinion/decision on a Paediatric investigation plan (PIP): Adtralza, Tralokinumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Skin and subcutaneous tissue disorders, PIP number: P/0012/2024
Submitted by Anonymous (not verified) on 14 March 2025 - 9:45
Opinion/decision on a Paediatric investigation plan (PIP): Adtralza, Tralokinumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Skin and subcutaneous tissue disorders, PIP number: P/0012/2024
Product Management Service (PMS) roadmap
Submitted by Anonymous (not verified) on 14 March 2025 - 8:15
Product Management Service (PMS) roadmap
Human medicines European public assessment report (EPAR): Silodyx, silodosin, Date of authorisation: 29/01/2010, Revision: 17, Status: Authorised
Submitted by Anonymous (not verified) on 14 March 2025 - 8:05
Human medicines European public assessment report (EPAR): Silodyx, silodosin, Date of authorisation: 29/01/2010, Revision: 17, Status: Authorised